Slideshow

OSA and Dyslipidemia: Beyond the Obesity Factor

Author(s):

Veronica Hackethal MD

Obstructive sleep apnea negatively impacts lipid levels, greatly increasing risk for CV disease and independent of obesity, according to the largest analysis of the link to date.

Related Videos
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
The APAC Recap: Dyslipidemia at CAPP Live 2024 with Viet Le, DMSc, PA-C | Image Credit: APAC
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
Steve Nissen, MD | Credit: Cleveland Clinic
Related Content
FDA Approves Tirzepatide for Obstructive Sleep Apnea in Obesity | Image Credit: US Food and Drug Administration
December 20th 2024

FDA Approves Tirzepatide for Obstructive Sleep Apnea in Obesity

Connor Iapoce
Prof. Kausik Ray: Inclisiran Data at ESC Congress 2020
September 3rd 2020

Prof. Kausik Ray: Inclisiran Data at ESC Congress 2020

Patrick Campbell
CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial | Image Credit: Novo Nordisk
December 20th 2024

CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial

Connor Iapoce
The State of Preventive Cardiology
August 28th 2020

The State of Preventive Cardiology

Kevin Kunzmann
LIB Therapeutics Submits Lerodalcibep BLA Targeting Reduction in Elevated LDL-C | Image Credit: US Food and Drug Administration
December 19th 2024

LIB Therapeutics Submits BLA for Lerodalcibep Targeting Reductions in LDL-C

Connor Iapoce
HCPLive Cardiology Month in Review: November 2024
December 1st 2024

Cardiology Month in Review: November 2024

Patrick Campbell Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.